Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Limitations and potential of Phase II PATRICIA trial in HER2+/HR+ advanced breast cancer

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, discussed the limitations and potential implications of the Phase II PATRICIA trial (NCT02448420), which investigates the combination of palbociclib, trastuzumab, and endocrine therapy in patients with previously treated HER2-positive, hormone receptor-positive (HR+/HER2+) PAM50 Luminal advanced breast cancer (ABC). As a Phase II randomized study, the trial faced recruitment challenges, leading to an amendment and a smaller-than-planned sample size. Despite these limitations, the trial offers a promising opportunity for patients with luminal A or B intrinsic subtypes within the HR-positive, HER2-positive disease category. These patients could potentially benefit from chemotherapy-free regimens. However, Dr Ciruelos emphasized that these findings need confirmation through new prospective trials to validate the efficacy and safety of such treatment approaches. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.